Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms.

BORIS DOI
Publisher DOI
PubMed ID
31660663
Description
Immune checkpoint inhibitor (ICI) therapy has demonstrated impressive antitumor activity. However, it causes adverse effects, including lichenoid reactions. Cases of ICI-triggered bullous pemphigoid (BP) and anecdotally mucous membrane pemphigoid (MMP) have also been reported. We describe two new cases of pembrolizumab-triggered MMP, one of which was associated with cutaneous lichenoid lesions.
Date of Publication
2020-02
Publication Type
Article
Subject(s)
Keyword(s)
Mucous membrane pemphigoid anti-PD-1 antibodies drug-triggered pemphigoid immune checkpoint inhibitors lichen lichenoid reaction pemphigoid
Language(s)
en
Contributor(s)
Additional Credits
Series
Journal of the European Academy of Dermatology and Venereology : JEADV
Publisher
Wiley
ISSN
1468-3083
Access(Rights)
open.access
Show full item